SLC5A2 and type 2 diabetes mellitus: Dapagliflozin (DAPA) is a highly selective SGLT2 inhibitor, and is used to treat T2DM by reducing renal glucose reabsorption and promoting urinary glucose excretion (Kasichayanula et al., 2014).